±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1640  |  »Ø¸´: 5

¼ÎµÑ

ľ³æ (СÓÐÃûÆø)


[½»Á÷] ¡¾ÇóÖú¡¿AC2993Ò»ÆÚ¡¢¶þÆÚÁÙ´²Ñо¿É걨×ÊÁÏ

¹òÇóAC2993Ò»ÆÚºÍ¶þÆÚÁÙ´²Ñо¿µÄÉ걨×ÊÁÏ£¬ÏÖÒª·­ÒëÁÙ´²Ñо¿ÓйØÔö´ó¼ÁÁ¿µÄ¸±·´Ó¦¡¢ÄÍÊÜÐÔ¡¢°²È«ÐԵȵÄÏà¹Ø×ÊÁÏ£¬¿ÉϧûÓеç×Ӱ棬±¾ÈËÓ¢ÎÄÄÜÁ¦ÓÐÏÞ£¬·­ÒëÆðÀ´±È½ÏÀ§ÄÑ£¬×îºÃÓÐÖÐÎİæµÄ£¬²»Ê¤¸Ð¼¤£¡
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

work or phd?

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ronalbeck

Òø³æ (ÕýʽдÊÖ)


¡ï ¡ï ¡ï ¡ï ¡ï
kidant(½ð±Ò+5):лл»ØÌû½»Á÷ 2010-11-03 09:10:28
¼ÎµÑ(½ð±Ò+5): 2010-11-24 10:42:17
Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination
This study has been completed.
First Received: September 3, 2002   Last Updated: November 5, 2007   History of Changes
Sponsor:  Amylin Pharmaceuticals, Inc.  
Collaborator:  Eli Lilly and Company

Information provided by:  Amylin Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:  NCT00044668

  Purpose
This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.


Condition  Intervention  Phase  
Diabetes Mellitus, Type 2
Drug: AC2993 (synthetic exendin-4)
Phase III



Study Type: Interventional  
Study Design: Allocation: Non-Randomized
Control: Uncontrolled
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination


Resource links provided by NLM:


MedlinePlus related topics: Diabetes
Drug Information available for: Exenatide Metformin Metformin hydrochloride
U.S. FDA Resources


Further study details as provided by Amylin Pharmaceuticals, Inc.:


Primary Outcome Measures:
•*Examine long-term effect on glucose control of subcutaneously (SC) injected AC2993 administered twice a day (BID) in subjects with type 2 diabetes (T2DM);*Assess long-term safety of SC injected AC2993 administered BID in subjects with T2DM


Secondary Outcome Measures:
•*Examine long-term effect on various pharmacodynamic measurements of SC injected AC2993 administered BID in subjects with T2DM.


Estimated Enrollment: 150
Study Start Date: August 2002
  Eligibility


Ages Eligible for Study:    20 Years to 75 Years
Genders Eligible for Study:    Both
Accepts Healthy Volunteers:    No

Criteria
Inclusion Criteria:

•Subjects with type 2 diabetes
•Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination
•BMI 25-45 kg/m^2
•HbA1c between 7.5 % and 12.0 %, inclusive
Exclusion Criteria:

•Treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening
•Patients previously treated with AC2993
•Patients presently treated with insulin
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00044668

Locations
Hungary
Peterfy Teaching Hospital
Budapest, Hungary, H 1076  
Diagnostic Units Hungary Kft.
Budapest, Hungary, H 1036  
Uzsoki Street Municipal Hospital
Budapest, Hungary, H 1145  
Sponsors and Collaborators
Amylin Pharmaceuticals, Inc.
Eli Lilly and Company
Investigators
Study Director: Lisa Porter, MD Amylin Pharmaceuticals, Inc.

  More Information

Additional Information:
Link to study results on ClinicalStudyResults.org   

No publications provided

ClinicalTrials.gov Identifier: NCT00044668     History of Changes  
Other Study ID Numbers: 2993-117
Study First Received: September 3, 2002
Last Updated: November 5, 2007
Health Authority: United States: Food and Drug Administration;   Hungary: National Institute of Pharmacy

Keywords provided by Amylin Pharmaceuticals, Inc.:
exenatide
exendin-4
diabetes
Amylin
Lilly



Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Exenatide
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
2Â¥2010-11-01 14:25:42
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ronalbeck

Òø³æ (ÕýʽдÊÖ)


¡ï ¡ï ¡ï ¡ï ¡ï
caoyuan521(½ð±Ò+2):ллÊÚÈËÒÔÓæ£¡ 2010-11-01 21:19:14
kidant(½ð±Ò+3):лл»ØÌû½»Á÷ 2010-11-03 09:10:37
http://clinicaltrials.gov/ct2/results?term=AC2993
Â¥Ö÷¿´ÏÂÕâ¸öÌû×Ó°É£¬Ó¢ÓﻹÊÇ×Ô¼º·­Òë°É£¬¿ÉÒÔ¶ÍÁ¶Ò»ÏÂˮƽ£¬·­ÒëÁ½Èý´ÎÄã¾Í¶¼ÊìϤÁË£¡
Ï£Íû¶ÔÄãÓаïÖú£¡
3Â¥2010-11-01 14:27:05
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

quchun12

Í­³æ (³õÈëÎÄ̳)

лл·ÖÏíÍøÒ³

ÒýÓûØÌû:
Originally posted by ronalbeck at 2010-11-01 14:27:05:
http://clinicaltrials.gov/ct2/results?term=AC2993
Â¥Ö÷¿´ÏÂÕâ¸öÌû×Ó°É£¬Ó¢ÓﻹÊÇ×Ô¼º·­Òë°É£¬¿ÉÒÔ¶ÍÁ¶Ò»ÏÂˮƽ£¬·­ÒëÁ½Èý´ÎÄã¾Í¶¼ÊìϤÁË£¡
Ï£Íû¶ÔÄãÓаïÖú£¡

Õâ¸öÍøÕ¾ÌýºÃÄØ£¡£¡
Enjoylife
4Â¥2010-11-03 08:44:24
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

deeplin

Ìú³æ (³õÈëÎÄ̳)

¡ï
kidant(½ð±Ò+1):лл»ØÌû½»Á÷ 2010-11-03 09:10:58
¶¥Ò»Ï£¬¿ÉÒÔÏÂÔØÁé¸ñ˹£¬»®´Ê·­ÒëºÜ·½±ã
5Â¥2010-11-03 09:00:41
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xiefl1984

ľ³æ (СÓÐÃûÆø)


¡ï ¡ï ¡ï
koria0727(½ð±Ò+3):¶àлÌṩ¡£ 2010-11-24 10:41:02
¼ÎµÑ(½ð±Ò+45):лл 2010-11-28 10:41:30
6Â¥2010-11-24 10:39:02
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ¼ÎµÑ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] £¨µ÷¼Á£©Ò»Ö¾Ô¸±¨¿¼¹þ¶û±õ¹¤Òµ´óѧ0857×ÊÔ´Óë»·¾³×¨Òµ378·Ö¿¼Éú +7 ºÝºÝ¼ÓÓÍ 2026-04-05 7/350 2026-04-05 22:31 by dongzh2009
[¿¼ÑÐ] 262Çóµ÷¼Á +7 ÌìϵÚÒ»ÎÄ 2026-04-04 8/400 2026-04-05 21:31 by ¼¤Á÷Ó¶É
[¿¼ÑÐ] 085602µ÷¼Á ³õÊÔ×Ü·Ö335 +8 19123253302 2026-04-05 8/400 2026-04-05 20:44 by ÄϺ½~ÍòÀÏʦ
[¿¼ÑÐ] 306·Ö²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +7 Àè°ÉÀ²À²ÄãºÜÓÐà 2026-04-03 7/350 2026-04-05 17:18 by Hdyxbekcb
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ£¬³õÊԳɼ¨350Çóµ÷¼Á +9 ÑØ°¶?±´¿Ç 2026-04-04 14/700 2026-04-05 01:09 by ÑØ°¶?±´¿Ç
[¿¼ÑÐ] 286Çóµ÷¼Á +3 ²Ýľ²»ÑÔ 2026-04-04 3/150 2026-04-04 22:40 by lbsjt
[¿¼ÑÐ] 085600µ÷¼Á +4 1amJJ 2026-04-02 4/200 2026-04-04 21:53 by hemengdong
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +12 Ò»ÑùYWY 2026-04-02 13/650 2026-04-04 20:49 by À¶ÔÆË¼Óê
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÄÏʦ·¶361·Ö£¬»¯Ñ§Çóµ÷¼Á +7 Nicole88888 2026-04-01 7/350 2026-04-04 18:28 by macy2011
[¿¼ÑÐ] 334Çóµ÷¼Á +9 Trying] 2026-03-31 9/450 2026-04-03 15:18 by ×ÁçíØ¼
[¿¼ÑÐ] Çóµ÷¼Á +4 15064154688 2026-04-03 5/250 2026-04-03 15:07 by zrongyan
[¿¼ÑÐ] 0705Àíѧ294Çóµ÷¼Á +3 ³É¹û³É¹ûcg5 2026-04-03 3/150 2026-04-03 14:04 by simons1972
[¿¼ÑÐ] Ò»Ö¾Ô¸aÇø211£¬085601-307·ÖÇóµ÷¼Á +13 µ³¼ÎºÀ 2026-03-31 26/1300 2026-04-03 08:33 by 495374996
[¿¼ÑÐ] ÍÁľ304Çóµ÷¼Á +4 ÍÃͻͻͻ£¬ 2026-04-02 5/250 2026-04-02 21:16 by ÍÃͻͻͻ£¬
[¿¼ÑÐ] 318Çóµ÷¼Á£¬¼ÆËã²ÄÁÏ·½Ïò +10 Îüß÷Óк¦óÏÃü 2026-04-01 11/550 2026-04-02 16:29 by oooqiao
[¿¼ÑÐ] ³õÊÔ301£¬´úÂë085701»·¾³¹¤³Ì£¬±¾Ë¶Ò»Ö£¬ËÄÁù¼¶Òѹý£¬ÓжþÇøÒ»×÷£¬¹²·¢±í5ƪÂÛÎÄ +6 axibli 2026-04-01 6/300 2026-04-02 13:42 by Ecowxq666£¡
[¿¼ÑÐ] ÉúÎïÓëÒ½Ò©¿¼Ñе÷¼Á +5 Ìúº©º©123425 2026-03-31 5/250 2026-04-01 18:01 by syh9288
[¿¼ÑÐ] 326Çóµ÷¼Á +4 áÌáÌ×Ð 2026-03-31 4/200 2026-04-01 09:58 by ÎҵĴ¬Îҵĺ£
[¿¼ÑÐ] 254²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +3 º²¶¬ÁÖéª 2026-03-30 4/200 2026-03-31 17:53 by yishunmin
[¿¼ÑÐ] 323·Ö ʳƷÓëÓªÑøµ÷¼Á +3 ºÙooo 2026-03-31 3/150 2026-03-31 09:38 by longlotian
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û